藥品合約開發和製造的市場規模、佔有率和成長分析（按服務、按最終用戶、按地區）：產業預測（2025-2032）

Pharmaceutical Contract Development and Manufacturing Market Size, Share, Growth Analysis, By Service (Pharmaceutical Manufacturing Services, Drug Development Services), By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年01月01日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023年全球藥品合約開發和製造市場規模將為1,222億美元，從2024年的1,306.3億美元成長到2032年的2,227.8億美元，預測期（2025-2032）複合年成長率預計將維持在6.9%。

由於多種因素的影響，包括尖端技術的採用增加、專利到期和研發投資活性化，藥品合約開發和製造市場正在經歷強勁成長。 COVID-19 大流行刺激了學名藥和生技藥品的需求，進一步推動了這種擴張。此外，對細胞和基因治療、個人化藥物、高活性藥物成分 (HPAPI) 和抗體藥物複合體(ADC) 的需求不斷成長也推動了市場成長。然而，引入序列化和缺乏合格專家等挑戰可能會阻礙進展。展望未來，企業必須利用這些動態，在不斷變化的環境中抓住新機會並保持成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭資訊

前5名企業對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分類的佔有率分析
- 收益與前一年同期比較（2022-2024）

主要企業簡介

Cambrex Corporation
Samsung Biologics Co., Ltd.
Siegfried Holdings AG
FUJIFILM Diosynth Biotechnologies
Aenova Group
Wuxi Biologics, Inc.
Aurobindo Pharma, Ltd.
Vetter Pharma International GmbH
Thermo Fisher Scientific, Inc.
Catalent, Inc
Recipharm AB
Almac Group
Lonza Group Ltd.
Piramal Enterprises Limited
Fabbrica Italiana Sintetici SpA
Fareva SA
CH Boehringer Sohn AG & Co. KG.
Jubilant Pharmova Limited
Curia Global, Inc.
Delpharm Holdings

結論和建議

簡介目錄

Product Code: SQMIG35J2034

Global Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 122.2 billion in 2023 and is poised to grow from USD 130.63 billion in 2024 to USD 222.78 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The pharmaceutical contract development and manufacturing market is experiencing robust growth driven by multiple factors, including the increasing adoption of advanced technologies, patent expirations, and heightened investments in research and development. Demand for generic medications and biologics, spurred by the COVID-19 pandemic, further fuels this expansion. The market is also poised for growth due to the rising need for cell and gene therapies, customized medicines, high potency active pharmaceutical ingredients (HPAPIs), and antibody-drug conjugates (ADCs). However, challenges such as the implementation of serialization and a shortage of qualified professionals may hinder progress. Moving forward, firms must navigate these dynamics to capitalize on emerging opportunities and sustain growth in this evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Contract Development And Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmaceutical Contract Development And Manufacturing Market Segmental Analysis

Global Pharmaceutical Contract Development and Manufacturing Market is segmented by Service, End User and region. Based on Service, the market is segmented into Pharmaceutical Manufacturing Services, Drug Development Services, Biologics Manufacturing Services and Packaging Services. Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-size Pharmaceutical Companies, Generic Pharmaceutical Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmaceutical Contract Development And Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market is experiencing significant growth due to the rising demand for pharmaceuticals targeting chronic illnesses. This demand is further bolstered by the numerous benefits of outsourcing, particularly in terms of cost and time efficiency. Companies in this sector are investing heavily in enhancing their infrastructure, workforce, and technological capabilities to capture a larger portion of the outsourcing market. This trend underscores the shift towards outsourcing as a strategic move for pharmaceutical firms looking to streamline operations and optimize resources, thus driving the overall expansion of the contract development and manufacturing landscape.

Restraints in the Global Pharmaceutical Contract Development And Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market faces significant restraints, particularly due to a shortage of skilled labor, which threatens to impede market growth. Inadequate understanding of production processes can lead to defective product lines, thereby eroding consumer trust. This lack of confidence poses a risk not only to the relationships among developers, manufacturers, and distributors but also to the overall integrity of the market. As a result, addressing workforce shortages and enhancing process knowledge are crucial to mitigate the potential negative impacts and ensure a reliable and effective contract development and manufacturing ecosystem in the pharmaceutical industry.

Market Trends of the Global Pharmaceutical Contract Development And Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market is experiencing significant growth, driven primarily by the rising incidence of cancer and advancements in technology that facilitate the development of safe and effective medications. This trend underscores a burgeoning demand for oncology treatments, leading to a heightened focus on highly potent New Chemical Entities (NCEs). As researchers and manufacturers prioritize the creation of selective compounds that optimize therapeutic efficacy while minimizing dosing frequencies, Contract Development and Manufacturing Organizations (CDMOs) are increasingly leveraged to expedite the drug development process, aligning with the industry's shift towards personalized medicine and targeted therapies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Regulatory Analysis
Case Studies

Global Pharmaceutical Contract Development and Manufacturing Market Size by Service & CAGR (2025-2032)

Market Overview
Pharmaceutical Manufacturing Services
- API Manufacturing Services
- FDF Manufacturing Services
Drug Development Services
Biologics Manufacturing Services
- API Manufacturing Services
- FDF Manufacturing Services
Packaging Services

Global Pharmaceutical Contract Development and Manufacturing Market Size by End User & CAGR (2025-2032)

Market Overview
Large Pharmaceutical Companies
Small and Mid-size Pharmaceutical Companies
Generic Pharmaceutical Companies
Others

Global Pharmaceutical Contract Development and Manufacturing Market Size & CAGR (2025-2032)

North America (Service, End User)
- US
- Canada
Europe (Service, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Service, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Service, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Service, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Cambrex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siegfried Holdings AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Diosynth Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aenova Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wuxi Biologics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vetter Pharma International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent, Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almac Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Enterprises Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fabbrica Italiana Sintetici S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fareva SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
C.H. Boehringer Sohn AG & Co. KG.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharmova Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curia Global, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Delpharm Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments